With support from the NIH Small Business Innovation Research (SBIR) program, Navidea Biopharmaceuticals is working to bring medical technologies to patients with rheumatoid arthritis, Kaposi’s sarcoma, and atherosclerosis.Specializing in developing innovative immunodiagnostic and...
You are here
Navidea Biopharmaceuticals, Inc.
Company Information
Information
UEI: GQWFJQX2UKJ2
# of Employees: 20
Ownership Information
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Gallium 68 Tilmanocept for PET Imaging of Atherosclerosis Plaques
Amount: $225,000.00Myocardial infarctionsMIor heart attacksischemic strokesISand peripheral artery diseasePADtogether considered cardiovascular diseaseCVDare all commonly caused by the same underlying pathologyatheroscl ...
STTRPhase I2019Department of Health and Human Services National Institutes of Health -
CD206 Targeted Therapy for Kaposi Sarcoma and Tumor Associated Macrophages
Amount: $1,541,545.00Summary AbstractKaposi sarcomaKSis a potentially life threatening consequence of immunosuppression in patients that are infected with human herpes virusHHVMost KS occurs in patients with acquired immu ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
CD206 Targeted Therapy for Kaposi Sarcoma and Tumor Associated Macrophages
Amount: $232,464.00DESCRIPTION provided by applicant Kaposi sarcoma KS is a potentially life threatening consequence of immunosuppression in patients that are infected with human herpes virus HHV Most KS occ ...
SBIRPhase I2016Department of Health and Human Services National Institutes of Health -
mTc Tilmanocept for Targeting Rheumatoid Arthritis RA Driving Macrophages
Amount: $1,500,000.00DESCRIPTION provided by applicant Navidea Biopharmaceuticals is seeking SBIR Fast Track grant support for preclinical animal studies and a regulatory phase clinical study of the ability of m ...
SBIRPhase II2016Department of Health and Human Services National Institutes of Health -
Receptor Mediated SPECT Imaging Of Kaposi Sarcoma With mTc Tilmanocept
Amount: $1,500,000.00DESCRIPTION provided by applicant Navidea Biopharmaceuticals has developed mTc tilmanocept as a radiopharmaceutical diagnostic imaging agent targeted to the macrophage mannose receptor CD to ...
SBIRPhase II2016Department of Health and Human Services National Institutes of Health -
99mTc-Tilmanocept Targeting of Cardiovascular Plaque in HIV Subjects
Amount: $321,838.00DESCRIPTION provided by applicant Navidea Biopharmaceuticals is seeking support to progress efforts designed ultimately to determine if its diagnostic imaging agent mTc tilmanocept can be used ...
SBIRPhase I2015Department of Health and Human Services National Institutes of Health -
CC49/RIGS, a diagnostic radiopharmaceutical monoclonal antibody, for enhanced liv
Amount: $1,226,270.00DESCRIPTION provided by applicant After an interim period of inactivity based on a select alternative commercial focus and after consultation with the FDA Neoprobe Corporation is rapidly reinitia ...
SBIRPhase II2015Department of Health and Human Services National Institutes of Health -
99mTc-Tilmanocept for Targeting Rheumatoid Arthritis (RA)-Driving Macrophages
Amount: $224,993.00DESCRIPTION provided by applicant Navidea Biopharmaceuticals is seeking SBIR Fast Track grant support for preclinical animal studies and a regulatory phase clinical study of the ability of m ...
SBIRPhase I2015Department of Health and Human Services National Institutes of Health -
99mTc-Tilmanocept for Sentinel Lymph Node Biopsy in Cervical Cancer Surgeries
Amount: $1,500,000.00DESCRIPTION provided by applicant Navidea Biopharmaceuticals Navidea is seeking SBIR FastTrack grant support to investigate the clinical utility safety and efficacy of its new product mTc ti ...
SBIRPhase II2015Department of Health and Human Services National Institutes of Health -
Receptor Mediated SPECT Imaging Of Kaposi Sarcoma With 99mTc-Tilmanocept
Amount: $300,000.00DESCRIPTION provided by applicant Navidea Biopharmaceuticals has developed mTc tilmanocept as a radiopharmaceutical diagnostic imaging agent targeted to the macrophage mannose receptor CD to ...
SBIRPhase I2015Department of Health and Human Services National Institutes of Health
